ÂÜÀòÂÒÂ×

Simon Glerup has a diverse work experience spanning various roles and companies. Simon started their career as a Postdoctoral Research Fellow at Aarhus University from February 2007 to December 2011. Simon then co-founded pAbmAbs in December 2011. In January 2012, they became an Assistant Professor at Aarhus University and later became an Associate Professor from March 2013 onwards.

In January 2014, Simon joined Mayo Clinic as a Visiting Associate Professor until October 2014. In 2017, they co-founded Draupnir Bio and held multiple roles including Co-Founder, CEO, Board Member, and CSO. Simon continued to be associated with Draupnir Bio until June 2021.

Simon also has affiliations with other companies. Simon joined Novo Nordisk Foundation in January 2019 as a Committee Member. In January 2020, they co-founded Teitur Trophics and Muna Therapeutics, holding the role of Co-Founder in both companies.

Overall, Simon Glerup has a strong background in academia and entrepreneurship, with experience in various leadership positions and co-founding multiple companies in the biotechnology and pharmaceutical fields.

Simon Glerup's education history includes pursuing a Doctor of Philosophy (PhD) in Molecular Biology from Aarhus University. There is no information provided regarding the start or end year of this degree. Additionally, Simon has attended the Cold Spring Harbor Laboratory, IMD, Universitat d'Alacant, Università degli Studi di Napoli Federico II, and Università degli Studi di Siena, but no specific degree or field of study is mentioned for these institutions.